{"id":4779,"date":"2023-06-01T07:11:29","date_gmt":"2023-06-01T07:11:29","guid":{"rendered":"https:\/\/www.nflbiosciences.com\/?page_id=4779"},"modified":"2026-02-10T16:19:15","modified_gmt":"2026-02-10T16:19:15","slug":"board-of-directors","status":"publish","type":"page","link":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/","title":{"rendered":"Board of Directors"},"content":{"rendered":"

<\/div><\/div>
<\/div>

Board of Directors<\/span><\/span><\/h1>
The Board of Directors comprises 5 members<\/div><\/header>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
\"bt_bb_section_bottom_section_coverage_image\"<\/div><\/section>
<\/div><\/div>
\r\n\t\t\t
\"Bruno<\/span><\/div>\r\n\t\t<\/div>

Chairman of the Board - Co-Founder & CEO<\/span>Bruno Lafont, M.Sc., Executive MBA<\/span><\/span><\/h3><\/header><\/div>
Bruno Lafont co-founded NFL Biosciences in 2009, Chairman of the Board, and CEO, he is in charge of the structuring and technical development of NFL Biosciences and its various projects.<\/p>\n

Previously, Bruno spent 12 years on the management team of PCM, an international French industrial group, as Innovation Director from 1999 to 2004, then as President and in charge of setting up the group's US subsidiary in Houston (Texas) from 2004 to 2009.<\/p>\n

Bruno holds an engineering degree in biochemistry from the Institut National des Sciences Appliqu\u00e9es (INSA) in Toulouse, a Master's degree in management from EMLyon, and an Executive MBA from the Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne and HEC Lausanne.<\/div>

<\/div>
<\/a><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div>
\r\n\t\t\t
\"Ignacio<\/span><\/div>\r\n\t\t<\/div>

Managing Director<\/span>Ignacio Faus, Ph.D., MBA<\/span><\/span><\/h3><\/header><\/div>
Dr. Ignacio Faus joined NFL Biosciences in 2019 as an investor, then the management team in early 2021.<\/p>\n

Dr. Ignacio Faus has 27 years' experience in large and medium-sized pharmaceutical companies, as well as in private and listed biotech companies: Bristol Myers Squibb, Grupo Uriach, Ferrer and co-founder in 2006 and Managing Director of Palau Pharma (sold in 2013). In recent years, Ignacio Faus has also been a director of several private and listed biotech companies and private equity funds in Europe and the United States.<\/p>\n

Ignacio holds a PhD in Biochemistry (Indiana University, USA) and an MBA in Entrepreneurship and Finance from the Kellogg School of Management (Northwestern University, USA).<\/div>

<\/div>
<\/a><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div>
\r\n\t\t\t
\"Francis<\/span><\/div>\r\n\t\t<\/div>

Board Member - Expert in Intellectual Property<\/span>Francis Ahner, M.Sc., Patent Attorney<\/span><\/span><\/h3><\/header><\/div>
Francis Ahner is Honorary President of the International Federation of Intellectual Property Attorneys (FICPI).
\nHe holds a degree in chemical engineering from ENSCS, a Master's degree in Law, Economics and Management from the University of Strasbourg, and a diploma from the Centre d'Etudes Internationales de la Propri\u00e9t\u00e9 Intellectuelle (CEIPI), where he taught for many years.
\nIn 1972, he joined Cabinet Regimbeau, where he became a partner. It was with this firm that he spent his entire career as an Intellectual Property Attorney and European Patent Attorney, advising leading French and foreign private companies and public bodies in the chemical field, and more specifically in pharmaceuticals and cosmetology. He has thus acquired in-depth experience in international litigation relating to the acquisition and defense of patent rights in France and abroad.<\/div>
<\/div>
<\/span><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div><\/div>
\r\n\t\t\t
\"Dominique<\/span><\/div>\r\n\t\t<\/div>

Board Member - Expert in go to market commercialization<\/span>Dominique C\u00f4t\u00e9<\/span><\/span><\/h3><\/header><\/div>
Dominique graduated in genetics and biotechnology from the Universit\u00e9 du Qu\u00e9bec \u00e0 Montr\u00e9al, has a certificate in administration from Laval University and in leadership from Cornell University (USA).
\nAfter spending time in research, she joined the pharmaceutical industry where she spent 30 years of her career with organizations such as Novartis, Pfizer, Zoetis and UCB. As a Chief Commercial Officer, she managed teams in more than 36 countries leading strategy optimization and deployment of new go to market models. With international experience and diverse knowledge of cultures and business; In 2018, she found her consulting firm, Cosawi,to help companies with their commercial excellence strategies,customer \/ patient engagement models and is an executive coach.Speaker and author in numerous business journals, in 2023 she is recognized as CEO of the Year for business transformations by AI \u2013 Influential businesswomen.<\/div>
<\/div>
<\/a><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div>
\r\n\t\t\t
\"Yannick<\/span><\/div>\r\n\t\t<\/div>

Board Member - Expert in Clinical Development<\/span>Yannick Pl\u00e9tan, M.D.<\/span><\/span><\/h3><\/header><\/div>
Yannick Pl\u00e9tan holds degrees in pneumology, immunology, clinical pharmacology and pharmacokinetics - post-doctorate at INSERM and visiting professor at the University of California Davis. After practicing hospital medicine for several years, he joined the pharmaceutical industry, where he held senior management positions for 20 years in R&D and medical affairs at Sanofi, Institut de Recherche Pierre Fabre, Pfizer and Roche-Genentech. He played a central role in the creation and worldwide development of the nicotine patch, and in the later development and launch of Chantix\u00ae.<\/div>
<\/div>
<\/a><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4779","page","type-page","status-publish","hentry"],"yoast_head":"\nBoard of Directors - NFL Biosciences<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Board of Directors - NFL Biosciences\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"NFL Biosciences\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T16:19:15+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/board-of-directors\\\/\",\"name\":\"Board of Directors - NFL Biosciences\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/#website\"},\"datePublished\":\"2023-06-01T07:11:29+00:00\",\"dateModified\":\"2026-02-10T16:19:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/board-of-directors\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/\",\"name\":\"NFL Biosciences\",\"description\":\"Rendre possible l'arr\u00eat du tabac\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nflbiosciences.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Board of Directors - NFL Biosciences","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Board of Directors - NFL Biosciences","og_url":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/","og_site_name":"NFL Biosciences","article_modified_time":"2026-02-10T16:19:15+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/","url":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/","name":"Board of Directors - NFL Biosciences","isPartOf":{"@id":"https:\/\/www.nflbiosciences.com\/en\/#website"},"datePublished":"2023-06-01T07:11:29+00:00","dateModified":"2026-02-10T16:19:15+00:00","breadcrumb":{"@id":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.nflbiosciences.com\/en\/board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.nflbiosciences.com\/en\/"},{"@type":"ListItem","position":2,"name":"Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.nflbiosciences.com\/en\/#website","url":"https:\/\/www.nflbiosciences.com\/en\/","name":"NFL Biosciences","description":"Rendre possible l'arr\u00eat du tabac","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nflbiosciences.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/pages\/4779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/comments?post=4779"}],"version-history":[{"count":21,"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/pages\/4779\/revisions"}],"predecessor-version":[{"id":6543,"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/pages\/4779\/revisions\/6543"}],"wp:attachment":[{"href":"https:\/\/www.nflbiosciences.com\/en\/wp-json\/wp\/v2\/media?parent=4779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}